Immediate Impact

4 by Nobel laureates 2 from Science/Nature 53 standout
Sub-graph 1 of 23

Citing Papers

The anti-PD-L1/CTLA-4 bispecific antibody KN046 plus lenvatinib in advanced unresectable or metastatic hepatocellular carcinoma: a phase II trial
2025 Standout
Tumor metabolic regulators: key drivers of metabolic reprogramming and the promising targets in cancer therapy
2025 Standout
1 intermediate paper

Works of Frank Tsai being referenced

Phase I study of the arginase inhibitor INCB001158 (1158) alone and in combination with pembrolizumab (PEM) in patients (Pts) with advanced/metastatic (adv/met) solid tumours
2019
Abstract CT112: Durvalumab + tremelimumab in patients with metastatic urothelial cancer
2018

Author Peers

Author Last Decade Papers Cites
Frank Tsai 272 95 172 148 36 459
Jii Bum Lee 306 127 180 164 46 507
Robert Aiken 189 71 217 114 36 551
Saif Zaman 337 43 169 175 38 496
Rosemarie Krupar 305 114 215 152 31 538
Houssein Abdul Sater 365 81 119 288 33 494
Antonio Cusmai 280 118 191 136 28 558
Yelena Novik 306 145 126 196 44 518
Andrew Cannon 239 49 244 128 23 482
David C. Qian 188 88 104 164 40 450
D Oberberg 183 43 145 156 22 493

All Works

Loading papers...

Rankless by CCL
2026